Literature DB >> 15470016

Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18).

Zsuzsa Bajtay1, Cornelia Speth, Anna Erdei, Manfred P Dierich.   

Abstract

In the present study, we demonstrate that macrophage-tropic HIV-1 opsonized by complement and limited amounts of anti-HIV-IgG causes up to 10-fold higher productive infection of human monocyte-derived dendritic cells than HIV treated with medium or HIV opsonized by Ab only. Enhanced infection is completely abolished by a mAb specific for the ligand-binding site of CD11b (i.e., alpha-chain of complement receptor 3, receptor for iC3b), proving the importance of complement receptor 3 in this process. Inhibition of complement activation by EDTA also prevents enhanced infection, further demonstrating the role of complement in virus uptake and productive infection. Since HIV is, even in the absence of Abs, regularly opsonized by complement, most probably the above-described mechanism plays a role during in vivo primary infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470016     DOI: 10.4049/jimmunol.173.8.4775

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).

Authors:  Robert J Boackle; Quang L Nguyen; Renata S Leite; Xiaofeng Yang; Jana Vesely
Journal:  Mol Immunol       Date:  2005-03-05       Impact factor: 4.407

2.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

3.  Impaired NK Cell Activation and Chemotaxis toward Dendritic Cells Exposed to Complement-Opsonized HIV-1.

Authors:  Rada Ellegård; Elisa Crisci; Jonas Andersson; Esaki M Shankar; Sofia Nyström; Jorma Hinkula; Marie Larsson
Journal:  J Immunol       Date:  2015-07-08       Impact factor: 5.422

Review 4.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 5.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

6.  Complement opsonization of HIV-1 results in decreased antiviral and inflammatory responses in immature dendritic cells via CR3.

Authors:  Rada Ellegård; Elisa Crisci; Adam Burgener; Christopher Sjöwall; Kenzie Birse; Garrett Westmacott; Jorma Hinkula; Jeffrey D Lifson; Marie Larsson
Journal:  J Immunol       Date:  2014-09-24       Impact factor: 5.422

7.  Integrin αXβ₂ is a leukocyte receptor for Candida albicans and is essential for protection against fungal infections.

Authors:  Samir Jawhara; Elzbieta Pluskota; Dmitriy Verbovetskiy; Olena Skomorovska-Prokvolit; Edward F Plow; Dmitry A Soloviev
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

8.  Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.

Authors:  Gülşen Özkaya Şahin; Birgitta Holmgren; Enas Sheik-Khalil; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Fredrik Månsson; Hans Norrgren; Peter Aaby; Eva Maria Fenyö; Marianne Jansson
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Complement receptor 3 promotes severe ross river virus-induced disease.

Authors:  Thomas E Morrison; Jason D Simmons; Mark T Heise
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.